Your browser doesn't support javascript.
loading
Familial Mediterranean fever in patients with inflammatory bowel diseases: A nationwide study from the epi-IIRN.
Kori, Michal; Buchuk, Rachel; Goldzweig, Ofra; Weisband, Yiska Loewenberg; Tal, Noa; Ben-Tov, Amir; Ledderman, Natan; Matz, Eran; Freiman, Moti; Dotan, Iris; Turner, Dan; Shouval, Dror S.
Affiliation
  • Kori M; Pediatric Gastroenterology, Kaplan Medical Center, Rehovot, Israel.
  • Buchuk R; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Goldzweig O; Juliet Keidan Institute of Pediatric Gastroenterology, The Eisenberg R&D Authority, Shaare Zedek Medical Center, the Hebrew University of Jerusalem, Israel.
  • Weisband YL; Pediatric Rheumatology, Kaplan Medical Center, Rehovot, Israel.
  • Tal N; Clalit Health Services, Clalit Research Institute, Tel-Aviv, Israel.
  • Ben-Tov A; Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
  • Ledderman N; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Matz E; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Freiman M; Maccabi Health Services, Tel-Aviv, Israel.
  • Dotan I; Meuhedet Health Services, Tel-Aviv, Israel.
  • Turner D; Leumit Health Services, Tel-Aviv, Israel.
  • Shouval DS; Faculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, Israel.
Article in En | MEDLINE | ID: mdl-38814796
ABSTRACT
BACKGROUND AND

AIMS:

Inflammatory Bowel Diseases (IBD) and Familial Mediterranean Fever (FMF) are auto-inflammatory diseases with common clinical and biological features. We aimed to determine their association and characterize the natural history in patients with both diagnoses.

METHODS:

Utilizing data from the epi-IIRN cohort, which includes 98% of Israel's population, we calculated the adjusted prevalence of FMF among IBD patients vs non-IBD controls. Case ascertainment of IBD was determined according to validated algorithms and for FMF by ICD-9 codes and colchicine purchase.

RESULTS:

In total, 34 375 IBD patients (56% Crohn's disease [CD] and 44% ulcerative colitis [UC]) were compared with 93 602 matched controls. Among IBD patients, 157 (0.5%) had FMF compared with 160 (0.2%) of non-IBD controls (OR = 2.68 [95%CI 2.2-3.3]; p< 0.001). Pediatric-onset IBD had a higher prevalence of FMF compared with adult-onset IBD (30/5,243 [0.6%] vs 127/29 132 [0.4%]), without statistical significanse (OR = 1.31 [0.88-1.96]; p= 0.2). FMF was more prevalent in CD (114/19 264 [0.6%]) than UC (43/15 111 [0.3%]; OR = 2.1 [1.5-3.0]), p< 0.001). FMF diagnosis preceded that of IBD in 130/157 cases (83%). FMF was associated with a more severe disease activity in UC patients at diagnosis, but not in CD patients. Outcomes were comparable between patients with CD+FMF vs CD alone; however in patients with UC+FMF, time to biologic treatment was shorter.

CONCLUSION:

FMF is more prevalent in IBD patients than in the general population, particularly in CD. The diagnosis of FMF precedes the diagnosis of IBD in most cases, and may be associated with a more severe course in UC.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2024 Document type: Article Affiliation country: Israel

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2024 Document type: Article Affiliation country: Israel